Showing results (1591-1600 of 3,474) with videos related to
Sort By:
Pageof 348
Clinical Pharmacokinetics|September 29, 2012
Inter-individual differences in baseline coagulation activities and their implications for international normalized ratio control during warfarin initiation therapyYosuke Ichimura, Harumi Takahashi, Michael T M Lee, et al.Clinical Pharmacokinetics|September 29, 2012
Pharmacokinetic optimization of antiretroviral therapy in pregnancyKajal Buckoreelall, Tim R Cressey, Jennifer R KingClinical Pharmacokinetics|July 11, 2012
Diabetes mellitus reduces the clearance of atorvastatin lactone: results of a population pharmacokinetic analysis in renal transplant recipients and in vitro studies using human liver microsomesMiroslav Dostalek, Wai-Johnn Sam, Komal R Paryani, et al.Clinical Pharmacokinetics|July 18, 2012
Single-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal functionMichelle Treitel, Thomas Marbury, Richard A Preston, et al.Clinical Pharmacokinetics|July 23, 1998
Clinical pharmacokinetics of vasodilators. Part IIR Kirsten, K Nelson, D Kirsten, et al.Clinical Pharmacokinetics|July 23, 1998
Pharmacokinetic and pharmacodynamic changes in the elderly. Clinical implicationsA Hämmerlein, H Derendorf, D T LowenthalClinical Pharmacokinetics|February 4, 2015
Drug transporters in the central nervous systemBruno Stieger, Bo GaoClinical Pharmacokinetics|February 11, 2015
Oral bioavailability: issues and solutions via nanoformulationsKamla Pathak, Smita RaghuvanshiClinical Pharmacokinetics|January 31, 2015
Effect of Hepatic Impairment on the Pharmacokinetics of Pradigastat, a Diacylglycerol Acyltransferase 1 (DGAT1) InhibitorMasaru Hirano, Dan Meyers, GangaRaju Golla, et al.Clinical Pharmacokinetics|February 1, 2015
Population Pharmacokinetics and Pharmacodynamics of Linagliptin in Patients with Type 2 Diabetes MellitusSilke Retlich, Vincent Duval, Ulrike Graefe-Mody, et al.Pageof 348